Sun Valley Gold Has Lifted By $3.05 Million Its Iamgold (IAG) Position, Last Week Bayer AG (ETR:BAYN) Analysts

June 19, 2017 - By Maria Brooks

Sun Valley Gold Llc increased Iamgold Corp (IAG) stake by 201.88% reported in 2016Q4 SEC filing. Sun Valley Gold Llc acquired 1.02M shares as Iamgold Corp (IAG)’s stock declined 1.76%. The Sun Valley Gold Llc holds 1.52 million shares with $5.87 million value, up from 503,206 last quarter. Iamgold Corp now has $2.32 billion valuation. The stock declined 1.39% or $0.07 reaching $4.98 on the news. About 6.33M shares traded. IAMGOLD Corp (USA) (NYSE:IAG) has risen 21.20% since June 19, 2016 and is uptrending. It has outperformed by 4.50% the S&P500.

Among 27 analysts covering Bayer (ETR:BAYN), 14 have Buy rating, 3 Sell and 10 Hold. Therefore 52% are positive. Bayer had 215 analyst reports since July 22, 2015 according to SRatingsIntel. Deutsche Bank upgraded the stock to “Buy” rating in Wednesday, April 13 report. As per Thursday, September 24, the company rating was upgraded by Citigroup. On Wednesday, March 16 the stock rating was maintained by Jefferies with “Hold”. Berenberg upgraded Bayer AG (ETR:BAYN) on Tuesday, August 11 to “Buy” rating. BNP Paribas maintained Bayer AG (ETR:BAYN) on Wednesday, May 25 with “Neutral” rating. Warburg Research upgraded Bayer AG (ETR:BAYN) rating on Friday, September 16. Warburg Research has “Buy” rating and €118 target. The stock of Bayer AG (ETR:BAYN) has “Hold” rating given on Wednesday, June 15 by Jefferies. The firm earned “Hold” rating on Thursday, October 27 by DZ BANK. JP Morgan maintained the shares of BAYN in report on Saturday, July 16 with “Neutral” rating. The rating was maintained by UBS on Tuesday, September 1 with “Neutral”. See Bayer AG (ETR:BAYN) latest ratings:

03/03/2017 Broker: BNP Paribas Rating: Neutral New Target: €103.00 Maintain
03/03/2017 Broker: Independent Research Rating: Hold New Target: €111.00 Maintain
02/03/2017 Broker: Bernstein Rating: Outperform New Target: €122.00 Upgrade
02/03/2017 Broker: Commerzbank Rating: Buy New Target: €119.00 Upgrade
02/03/2017 Broker: Jefferies Rating: Buy New Target: €130.00 Upgrade
28/02/2017 Broker: DZ BANK Rating: Hold Maintain
24/02/2017 Broker: Deutsche Bank Rating: Buy New Target: €120.00 Upgrade
23/02/2017 Broker: Landesbank Rating: Hold New Target: €108.00 Maintain
23/02/2017 Broker: S&P Research Rating: Buy New Target: €120.00 Upgrade
23/02/2017 Broker: Independent Research Rating: Hold New Target: €111.00 Maintain

Among 14 analysts covering Iamgold Corp (NYSE:IAG), 4 have Buy rating, 4 Sell and 6 Hold. Therefore 29% are positive. Iamgold Corp had 26 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Sell” rating by Canaccord Genuity given on Wednesday, October 21. The firm earned “Reduce” rating on Monday, October 26 by HSBC. The company was downgraded on Friday, February 19 by Mackie. Raymond James downgraded IAMGOLD Corp (USA) (NYSE:IAG) on Friday, July 24 to “Underperform” rating. The rating was maintained by Raymond James with “Market Perform” on Thursday, June 15. The rating was downgraded by Credit Suisse to “Underperform” on Friday, January 13. The stock of IAMGOLD Corp (USA) (NYSE:IAG) has “Buy” rating given on Tuesday, November 8 by TD Securities. The company was reinitiated on Wednesday, November 25 by Morgan Stanley. Raymond James upgraded the stock to “Market Perform” rating in Thursday, January 21 report. The firm has “Underperform” rating by IBC given on Friday, July 24.

The stock increased 0.41% or EUR 0.5 on June 19, reaching EUR 123.3. About 1.53M shares traded. Bayer AG (ETR:BAYN) has 0.00% since June 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Bayer AG is a life science company. The Company’s divisions are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The company has market cap of 101.96 billion EUR. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. It has a 21.81 P/E ratio. The Pharmaceuticals division also comprises the radiology business.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: